Intrinsic value of DexCom - DXCM

Previous Close

$57.34

  Intrinsic Value

$0.79

stock screener

  Rating & Target

str. sell

-99%

Previous close

$57.34

 
Intrinsic value

$0.79

 
Up/down potential

-99%

 
Rating

str. sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of DXCM stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

Please visit our new site that uses elements of artificial intelligence for stock valuation: artificial intelligence value of DexCom (DXCM) stock.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  42.54
  24.20
  22.28
  20.55
  19.00
  17.60
  16.34
  15.20
  14.18
  13.26
  12.44
  11.69
  11.03
  10.42
  9.88
  9.39
  8.95
  8.56
  8.20
  7.88
  7.59
  7.33
  7.10
  6.89
  6.70
  6.53
  6.38
  6.24
  6.12
  6.00
  5.90
Revenue, $m
  573
  712
  870
  1,049
  1,248
  1,468
  1,708
  1,968
  2,247
  2,545
  2,861
  3,196
  3,548
  3,918
  4,305
  4,709
  5,131
  5,570
  6,027
  6,502
  6,996
  7,509
  8,042
  8,596
  9,172
  9,771
  10,394
  11,043
  11,719
  12,422
  13,156
Variable operating expenses, $m
 
  740
  904
  1,090
  1,297
  1,525
  1,774
  2,044
  2,333
  2,643
  2,971
  3,317
  3,683
  4,067
  4,469
  4,889
  5,326
  5,782
  6,256
  6,749
  7,262
  7,795
  8,348
  8,923
  9,521
  10,143
  10,790
  11,464
  12,165
  12,895
  13,657
Fixed operating expenses, $m
 
  43
  44
  45
  46
  48
  49
  50
  51
  52
  54
  55
  56
  58
  59
  61
  62
  64
  66
  67
  69
  71
  72
  74
  76
  78
  80
  82
  84
  86
  88
Total operating expenses, $m
  637
  783
  948
  1,135
  1,343
  1,573
  1,823
  2,094
  2,384
  2,695
  3,025
  3,372
  3,739
  4,125
  4,528
  4,950
  5,388
  5,846
  6,322
  6,816
  7,331
  7,866
  8,420
  8,997
  9,597
  10,221
  10,870
  11,546
  12,249
  12,981
  13,745
Operating income, $m
  -64
  -71
  -78
  -86
  -95
  -105
  -115
  -126
  -138
  -150
  -164
  -177
  -192
  -207
  -223
  -240
  -258
  -276
  -295
  -315
  -335
  -356
  -379
  -401
  -425
  -450
  -476
  -502
  -530
  -559
  -589
EBITDA, $m
  -49
  -53
  -56
  -60
  -64
  -68
  -73
  -78
  -83
  -88
  -94
  -100
  -107
  -113
  -120
  -127
  -135
  -143
  -151
  -159
  -168
  -177
  -186
  -196
  -206
  -216
  -227
  -238
  -250
  -262
  -274
Interest expense (income), $m
  0
  0
  1
  2
  3
  5
  7
  8
  10
  12
  14
  17
  19
  22
  24
  27
  30
  33
  36
  40
  43
  47
  50
  54
  58
  63
  67
  71
  76
  81
  86
Earnings before tax, $m
  -65
  -71
  -79
  -88
  -98
  -109
  -121
  -134
  -148
  -163
  -178
  -193
  -211
  -229
  -248
  -267
  -288
  -309
  -331
  -354
  -378
  -403
  -429
  -456
  -484
  -513
  -543
  -574
  -606
  -640
  -675
Tax expense, $m
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -66
  -71
  -79
  -88
  -98
  -109
  -121
  -134
  -148
  -163
  -178
  -193
  -211
  -229
  -248
  -267
  -288
  -309
  -331
  -354
  -378
  -403
  -429
  -456
  -484
  -513
  -543
  -574
  -606
  -640
  -675

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  124
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  403
  346
  424
  511
  608
  715
  831
  958
  1,094
  1,239
  1,393
  1,556
  1,727
  1,907
  2,096
  2,293
  2,498
  2,712
  2,934
  3,165
  3,406
  3,656
  3,915
  4,185
  4,465
  4,757
  5,061
  5,376
  5,705
  6,048
  6,405
Adjusted assets (=assets-cash), $m
  279
  346
  424
  511
  608
  715
  831
  958
  1,094
  1,239
  1,393
  1,556
  1,727
  1,907
  2,096
  2,293
  2,498
  2,712
  2,934
  3,165
  3,406
  3,656
  3,915
  4,185
  4,465
  4,757
  5,061
  5,376
  5,705
  6,048
  6,405
Revenue / Adjusted assets
  2.054
  2.058
  2.052
  2.053
  2.053
  2.053
  2.055
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.055
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
  2.054
Average production assets, $m
  84
  104
  127
  153
  182
  214
  249
  287
  328
  372
  418
  467
  518
  572
  629
  688
  749
  813
  880
  949
  1,021
  1,096
  1,174
  1,255
  1,339
  1,427
  1,518
  1,612
  1,711
  1,814
  1,921
Working capital, $m
  178
  67
  82
  99
  117
  138
  161
  185
  211
  239
  269
  300
  334
  368
  405
  443
  482
  524
  567
  611
  658
  706
  756
  808
  862
  918
  977
  1,038
  1,102
  1,168
  1,237
Total debt, $m
  0
  29
  62
  99
  141
  186
  236
  290
  348
  410
  476
  545
  619
  695
  776
  860
  948
  1,039
  1,134
  1,233
  1,335
  1,442
  1,553
  1,668
  1,788
  1,912
  2,042
  2,177
  2,317
  2,463
  2,616
Total liabilities, $m
  119
  148
  181
  218
  260
  305
  355
  409
  467
  529
  595
  664
  738
  814
  895
  979
  1,067
  1,158
  1,253
  1,352
  1,454
  1,561
  1,672
  1,787
  1,907
  2,031
  2,161
  2,296
  2,436
  2,582
  2,735
Total equity, $m
  284
  199
  243
  293
  348
  410
  476
  549
  627
  710
  798
  892
  990
  1,093
  1,201
  1,314
  1,431
  1,554
  1,681
  1,814
  1,952
  2,095
  2,243
  2,398
  2,559
  2,726
  2,900
  3,081
  3,269
  3,465
  3,670
Total liabilities and equity, $m
  403
  347
  424
  511
  608
  715
  831
  958
  1,094
  1,239
  1,393
  1,556
  1,728
  1,907
  2,096
  2,293
  2,498
  2,712
  2,934
  3,166
  3,406
  3,656
  3,915
  4,185
  4,466
  4,757
  5,061
  5,377
  5,705
  6,047
  6,405
Debt-to-equity ratio
  0.000
  0.150
  0.260
  0.340
  0.400
  0.450
  0.500
  0.530
  0.560
  0.580
  0.600
  0.610
  0.620
  0.640
  0.650
  0.650
  0.660
  0.670
  0.670
  0.680
  0.680
  0.690
  0.690
  0.700
  0.700
  0.700
  0.700
  0.710
  0.710
  0.710
  0.710
Adjusted equity ratio
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573
  0.573

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -66
  -71
  -79
  -88
  -98
  -109
  -121
  -134
  -148
  -163
  -178
  -193
  -211
  -229
  -248
  -267
  -288
  -309
  -331
  -354
  -378
  -403
  -429
  -456
  -484
  -513
  -543
  -574
  -606
  -640
  -675
Depreciation, amort., depletion, $m
  15
  18
  22
  26
  31
  36
  42
  48
  55
  62
  70
  76
  85
  94
  103
  113
  123
  133
  144
  156
  167
  180
  192
  206
  220
  234
  249
  264
  280
  297
  315
Funds from operations, $m
  50
  -53
  -57
  -62
  -67
  -73
  -79
  -86
  -93
  -101
  -109
  -117
  -126
  -135
  -145
  -155
  -165
  -176
  -187
  -199
  -211
  -223
  -237
  -250
  -264
  -279
  -294
  -309
  -326
  -343
  -360
Change in working capital, $m
  -6
  13
  15
  17
  19
  21
  23
  24
  26
  28
  30
  31
  33
  35
  36
  38
  40
  41
  43
  45
  46
  48
  50
  52
  54
  56
  59
  61
  63
  66
  69
Cash from operations, $m
  56
  -66
  -72
  -79
  -86
  -94
  -102
  -110
  -119
  -129
  -138
  -148
  -159
  -170
  -181
  -193
  -205
  -217
  -230
  -243
  -257
  -272
  -287
  -302
  -318
  -335
  -352
  -370
  -389
  -409
  -429
Maintenance CAPEX, $m
  0
  -14
  -17
  -21
  -25
  -30
  -35
  -41
  -47
  -54
  -61
  -68
  -76
  -85
  -94
  -103
  -113
  -123
  -133
  -144
  -156
  -167
  -180
  -192
  -206
  -220
  -234
  -249
  -264
  -280
  -297
New CAPEX, $m
  -56
  -20
  -23
  -26
  -29
  -32
  -35
  -38
  -41
  -44
  -46
  -49
  -51
  -54
  -57
  -59
  -62
  -64
  -67
  -69
  -72
  -75
  -78
  -81
  -84
  -87
  -91
  -95
  -99
  -103
  -107
Cash from investing activities, $m
  -56
  -34
  -40
  -47
  -54
  -62
  -70
  -79
  -88
  -98
  -107
  -117
  -127
  -139
  -151
  -162
  -175
  -187
  -200
  -213
  -228
  -242
  -258
  -273
  -290
  -307
  -325
  -344
  -363
  -383
  -404
Free cash flow, $m
  0
  -100
  -113
  -126
  -140
  -156
  -172
  -189
  -207
  -226
  -245
  -266
  -287
  -309
  -331
  -355
  -379
  -404
  -430
  -457
  -485
  -514
  -544
  -576
  -608
  -642
  -677
  -714
  -752
  -792
  -834
Issuance/(repayment) of debt, $m
  -2
  29
  33
  37
  41
  46
  50
  54
  58
  62
  66
  70
  73
  77
  80
  84
  88
  91
  95
  99
  103
  107
  111
  115
  120
  125
  130
  135
  140
  146
  152
Issuance/(repurchase) of shares, $m
  10
  110
  124
  138
  154
  171
  188
  207
  226
  246
  266
  287
  309
  332
  356
  380
  405
  432
  459
  487
  516
  546
  578
  610
  644
  680
  716
  755
  795
  836
  880
Cash from financing (excl. dividends), $m  
  8
  139
  157
  175
  195
  217
  238
  261
  284
  308
  332
  357
  382
  409
  436
  464
  493
  523
  554
  586
  619
  653
  689
  725
  764
  805
  846
  890
  935
  982
  1,032
Total cash flow (excl. dividends), $m
  8
  38
  44
  50
  55
  61
  66
  71
  77
  82
  87
  91
  95
  100
  105
  109
  114
  119
  124
  129
  134
  139
  144
  150
  156
  162
  169
  176
  183
  191
  199
Retained Cash Flow (-), $m
  -63
  -110
  -124
  -138
  -154
  -171
  -188
  -207
  -226
  -246
  -266
  -287
  -309
  -332
  -356
  -380
  -405
  -432
  -459
  -487
  -516
  -546
  -578
  -610
  -644
  -680
  -716
  -755
  -795
  -836
  -880
Prev. year cash balance distribution, $m
 
  124
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  53
  -80
  -89
  -99
  -110
  -122
  -135
  -149
  -164
  -180
  -196
  -214
  -232
  -251
  -271
  -291
  -313
  -335
  -358
  -382
  -407
  -433
  -460
  -488
  -517
  -548
  -579
  -612
  -646
  -681
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  51
  -73
  -77
  -82
  -85
  -89
  -91
  -93
  -94
  -94
  -93
  -91
  -88
  -84
  -79
  -74
  -68
  -62
  -55
  -49
  -42
  -36
  -30
  -25
  -20
  -16
  -12
  -9
  -7
  -5
Current shareholders' claim on cash, %
  100
  93.6
  88.1
  83.3
  79.2
  75.5
  72.2
  69.2
  66.4
  63.9
  61.6
  59.5
  57.5
  55.6
  53.9
  52.2
  50.6
  49.2
  47.8
  46.4
  45.1
  43.9
  42.7
  41.6
  40.5
  39.5
  38.4
  37.5
  36.5
  35.6
  34.7

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

FINANCIAL RATIOS  of  DexCom (DXCM)

Valuation Ratios
P/E Ratio -73.5
Price to Sales 8.5
Price to Book 17.1
Price to Tangible Book
Price to Cash Flow 86.6
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate 42.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 69.7%
Cap. Spend. - 3 Yr. Gr. Rate 47.6%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -19%
Ret/ On Assets - 3 Yr. Avg. -19.2%
Return On Total Capital -26%
Ret/ On T. Cap. - 3 Yr. Avg. -25.4%
Return On Equity -26.1%
Return On Equity - 3 Yr. Avg. -26%
Asset Turnover 1.6
Profitability Ratios
Gross Margin 66%
Gross Margin - 3 Yr. Avg. 67.7%
EBITDA Margin -8.7%
EBITDA Margin - 3 Yr. Avg. -8.6%
Operating Margin -11.2%
Oper. Margin - 3 Yr. Avg. -11.3%
Pre-Tax Margin -11.3%
Pre-Tax Margin - 3 Yr. Avg. -11.4%
Net Profit Margin -11.5%
Net Profit Margin - 3 Yr. Avg. -11.5%
Effective Tax Rate -1.5%
Eff/ Tax Rate - 3 Yr. Avg. -0.5%
Payout Ratio 0%

DXCM stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the DXCM stock intrinsic value calculation we used $573 million for the last fiscal year's total revenue generated by DexCom. The default revenue input number comes from 2016 income statement of DexCom. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our DXCM stock valuation model: a) initial revenue growth rate of 24.2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for DXCM is calculated based on our internal credit rating of DexCom, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of DexCom.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of DXCM stock the variable cost ratio is equal to 104%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $42 million in the base year in the intrinsic value calculation for DXCM stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for DexCom.

Corporate tax rate of 27% is the nominal tax rate for DexCom. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the DXCM stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for DXCM are equal to 14.6%.

Life of production assets of 6.1 years is the average useful life of capital assets used in DexCom operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for DXCM is equal to 9.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $284 million for DexCom - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 86.775 million for DexCom is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of DexCom at the current share price and the inputted number of shares is $5.0 billion.

RELATED COMPANIES Price Int.Val. Rating
JNJ Johnson&Johnso 133.15 146.14  hold
ABT Abbott Laborat 60.17 400.89  str.buy
WST West Pharmaceu 87.45 49.05  str.sell
CAH Cardinal Healt 69.34 123.25  str.buy

COMPANY NEWS

▶ DexCom Announces Upcoming Conference Presentations   [Feb-12-18 08:00AM  Business Wire]
▶ Fitbit for Kids? FIT Considering Smartwatch for Children   [Jan-09-18 01:12PM  InvestorPlace]
▶ 4 MedTech Stocks to Explode in 2018   [Dec-22-17 02:33PM  Zacks]
▶ DexCom Announces Upcoming Conference Presentation   [Dec-12-17 08:00AM  Business Wire]
▶ ETFs with exposure to DexCom, Inc. : December 8, 2017   [Dec-08-17 12:42PM  Capital Cube]
▶ ETFs with exposure to DexCom, Inc. : November 27, 2017   [Nov-27-17 01:13PM  Capital Cube]
▶ 3 Top Medical Device Stocks to Buy Now   [Nov-18-17 11:32AM  Motley Fool]
▶ ETFs with exposure to DexCom, Inc. : November 17, 2017   [Nov-17-17 11:44AM  Capital Cube]
▶ DexCom Announces Upcoming Conference Presentation   [Nov-09-17 08:00AM  Business Wire]
▶ ETFs with exposure to DexCom, Inc. : November 6, 2017   [Nov-06-17 11:28AM  Capital Cube]
▶ Why Fitbit Inc Stock Can Climb Back Out of Its Grave   [Nov-02-17 12:04PM  InvestorPlace]
▶ DexCom reports 3Q loss   [Nov-01-17 04:08PM  Associated Press]
▶ DexCom, Inc. to Host Earnings Call   [09:40AM  ACCESSWIRE]
▶ The 3 Best Diabetes Stocks to Buy in 2018   [Oct-30-17 09:33AM  Motley Fool]
▶ ETFs with exposure to DexCom, Inc. : October 27, 2017   [Oct-27-17 10:52AM  Capital Cube]
▶ DexCom Announces Upcoming Conference Presentation   [Oct-19-17 08:30AM  Business Wire]
▶ ETFs with exposure to DexCom, Inc. : October 17, 2017   [Oct-17-17 09:40AM  Capital Cube]
▶ DexCom's Quiet Consolidation After Huge Decline   [Oct-09-17 01:26PM  Benzinga]
▶ ETFs with exposure to DexCom, Inc. : October 6, 2017   [Oct-06-17 10:46AM  Capital Cube]
▶ 5 Top Stocks for October   [Oct-04-17 08:45PM  Motley Fool]
▶ What Happened in the Stock Market Today   [Sep-28-17 05:00PM  Motley Fool]
▶ Why DexCom Stock Is Getting Crushed Today   [11:53AM  Motley Fool]
▶ DexCom: Stay Sweet or Go Sour?   [11:00AM  Barrons.com]
▶ Fitbit Stock Briefly Touches New Highs   [10:59AM  Investopedia]
▶ Fitbit Inc (FIT) Stock Looks Good for the Very Short Term   [Sep-26-17 07:18AM  InvestorPlace]
▶ Fitbit Stock Tests Support After Breakout Fizzles   [Sep-20-17 01:06PM  Investopedia]
▶ Fitbit Inc (NYSE:FIT) Stock Still Has A Lot of Work To Do   [Sep-19-17 09:14AM  InvestorPlace]
▶ DexCom Announces Upcoming Conference Presentation   [Sep-08-17 05:22PM  Business Wire]
▶ Why Fitbit Stock Is Soaring Today   [12:37PM  Motley Fool]
Financial statements of DXCM
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.